Hemostemix Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HMTXF research report →
Companywww.hemostemix.com
Hemostemix Inc. , a biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. The company develops cell therapy products from the patient's own blood, which is a non-invasive source of therapeutic cells.
- CEO
- Thomas A. Smeenk
- IPO
- 2016
- Employees
- 12
- HQ
- Calgary, AB, CA
Price Chart
Valuation
- Market Cap
- $7.93M
- P/E
- -2.49
- P/S
- 0.00
- P/B
- -2.36
- EV/EBITDA
- -3.50
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 81.73%
- ROIC
- 672.36%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-4,710,088.7 · -80.05%
- EPS
- $-0.03 · -4.73%
- Op Income
- $-5,628,274
- FCF YoY
- -138.21%
Performance & Tape
- 52W High
- $0.12
- 52W Low
- $0.04
- 50D MA
- $0.05
- 200D MA
- $0.06
- Beta
- 0.95
- Avg Volume
- 2.84K
Get TickerSpark's AI analysis on HMTXF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our HMTXF Coverage
We haven't published any research on HMTXF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate HMTXF Report →